hsa_circ_0004018 suppresses the progression of liver fibrosis through regulating the hsa-miR-660-3p/TEP1 axis.
Animals
Benzofurans
/ pharmacology
Biomarkers
/ metabolism
Carbon Tetrachloride
/ toxicity
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cells, Cultured
Computational Biology
Disease Models, Animal
Disease Progression
Down-Regulation
Hepatic Stellate Cells
/ drug effects
Humans
Liver
/ drug effects
Liver Cirrhosis
/ chemically induced
Male
Mice
Mice, Transgenic
MicroRNAs
/ metabolism
Primary Cell Culture
RNA, Circular
/ genetics
RNA-Binding Proteins
/ genetics
Transfection
circular RNA
hepatic stellate cells
liver fibrosis
microRNA
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
25 06 2020
25 06 2020
Historique:
received:
09
11
2019
accepted:
17
04
2020
pubmed:
26
6
2020
medline:
10
3
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Efforts have been made in the prevention and treatment of liver fibrosis. The inhibition or depletion of the hepatic stellate cells (HSCs) has been considered as a potential approach. Recently, there are numbers of studies about the role of the circular RNA in the disease progression. However, the role of circular RNA in the regulation of HSCs and the progression of liver fibrosis remained elusive. In this study, we constructed a CCl4-induced liver fibrosis mouse model and overexpressed hsa_circ_0004018 in HSCs. Then, salvianolic acid B was used to treat HSCs
Identifiants
pubmed: 32584784
pii: 103257
doi: 10.18632/aging.103257
pmc: PMC7343491
doi:
Substances chimiques
Benzofurans
0
Biomarkers
0
MIRN660 microRNA, human
0
MicroRNAs
0
RNA, Circular
0
RNA-Binding Proteins
0
TEP1 protein, human
0
salvianolic acid B
C1GQ844199
Carbon Tetrachloride
CL2T97X0V0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11517-11529Commentaires et corrections
Type : ErratumIn
Références
Cytokine. 2019 Dec;124:154497
pubmed: 30097286
World J Gastroenterol. 2002 Aug;8(4):679-85
pubmed: 12174378
Gut Liver. 2019 Jan 15;13(1):11-15
pubmed: 30400735
World J Gastroenterol. 2016 Dec 28;22(48):10512-10522
pubmed: 28082803
PLoS One. 2017 May 4;12(5):e0176173
pubmed: 28472150
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Acta Biochim Biophys Sin (Shanghai). 2014 Apr;46(4):291-8
pubmed: 24389643
Cell Physiol Biochem. 2017;44(1):333-344
pubmed: 29132134
Biosci Trends. 2019;13(1):70-76
pubmed: 30867373
Front Pharmacol. 2019 Apr 11;10:322
pubmed: 31031620
Compr Physiol. 2013 Oct;3(4):1473-92
pubmed: 24265236
Gut. 2018 Sep;67(9):1704-1715
pubmed: 28754776
Science. 1997 Feb 14;275(5302):973-7
pubmed: 9020079
J Cell Physiol. 2018 Jun;233(6):4408-4422
pubmed: 28833094
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411
pubmed: 28487545
Curr Gene Ther. 2019;19(5):305-317
pubmed: 31696817
Zhongguo Zhong Yao Za Zhi. 2010 Jan;35(1):71-5
pubmed: 20349720
Cell. 2009 Aug 7;138(3):592-603
pubmed: 19665978
Cell Biosci. 2018 Dec 6;8:63
pubmed: 30534359
Sci Immunol. 2018 Oct 26;3(28):
pubmed: 30366940
Adv Drug Deliv Rev. 2017 Nov 1;121:27-42
pubmed: 28506744
Cell Death Dis. 2018 May 22;9(6):599
pubmed: 29789538
Evid Based Complement Alternat Med. 2012;2012:160726
pubmed: 23243430
Hepatology. 2018 Feb;67(2):736-749
pubmed: 28902427
Basic Clin Pharmacol Toxicol. 2019 Nov 11;:
pubmed: 31709714
Trends Genet. 2016 May;32(5):309-316
pubmed: 27050930
Oncotarget. 2017 Apr 6;8(35):58405-58416
pubmed: 28938566
Methods Mol Biol. 2017;1627:165-191
pubmed: 28836201
Cancer Med. 2018 Jun 1;:
pubmed: 29856133
Metabolism. 2015 Nov;64(11):1386-94
pubmed: 26362725
Nat Protoc. 2015 Feb;10(2):305-15
pubmed: 25612230
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3297-305
pubmed: 25074909